Answers are grounded in this paper and cite their sources.
Systematic review reveals significant anticancer effects and NK cell activity in standardized atine extracts, suggesting their therapeutic potential.
Background: Natural products remain a crucial source for anticancer and immunomodulatory therapy development. Standardized Atine extracts, containing defined bioactive compounds, show promising therapeutic potential, but systematic efficacy evaluation is lacking. Objective: To comprehensively evaluate the anticancer and immunomodulatory properties of standardized Atine extracts and their main components through systematic review and meta-analysis. Methods: Systematic search was conducted in PubMed, Embase, Cochrane Library, Web of Science, and SCOPUS (January 2000 – July 2025) according to PRISMA 2020 guidelines. Studies assessing the bioactivity of key Atine extract components were included: isoalantolactone, osthole, asarone, α-linolenic acid, and furfural derivatives. Random-effects models were used for meta-analysis. Results: A total of 23 studies met the inclusion criteria, encompassing 4,345 participants across in vitro, animal, and clinical studies. The meta-analysis revealed significant cytotoxic activity with pooled IC₅₀ values of 18.4 μM (95% CI: 15.2–21.6; I² = 34%). Animal studies demonstrated a 52.3% reduction in tumor volume (95% CI: 48.7–55.9%; I² = 39%). Clinical studies indicated improved overall survival (HR = 0.73; 95% CI: 0.62–0.86; I² = 28%). Immunomodulatory effects included a 38.2% increase in NK cell activity (95% CI: 34.1–42.3%; I² = 31%) and significant cytokine modulation. Conclusions: Standardized Atine extracts demonstrate significant anticancer and immunomodulatory potential through multitarget mechanisms. Well-designed clinical trials are needed to validate preclinical findings.
No takes yet. Share an insight, caveat, or question.
Bombushkar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: